MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jtd-2025-1159

Медицинская библиотека · Journal of thoracic disease · 2025

What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.

Oscullo Grace, Méndez Raúl, Olveira Casilda, Girón Rosa, García-Clemente Marta, Máiz Luis, Sibila Oriol, Golpe Rafael, Rodríguez-Hermosa Juan Luis, Barreiro Esther, Prados Concepción, Rodríguez-Lopez Juan, de la Rosa David, Martinez-García Miguel Ángel

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Bronchiectasis is characterized by excessive respiratory secretions, the management of which is clinically significant. Among the available pharmacological treatments, mucolytics play a pivotal role. N-acetylcysteine (N-AC) is the most commonly used mucolytic; however, the optimal dosing regimen remains inadequately defined. The primary aim of the present study is to specifically evaluate the efficacy of 1,200 mg/day of N-AC compared to 600 mg/day in patients with bronchiectasis.

METHODS

This was a retrospective, longitudinal, observational, multi-center study conducted across 43 centers, involving a cohort of 2,461 adult patients diagnosed with bronchiectasis based on a stable clinical state receiving either 600 mg/day of N-AC (n=252) or 1,200 mg/day (n=116), and provided follow-up data were available for 2 years. Propensity score matching (PSM) was employed to balance baseline characteristics between groups. Final outcomes were further adjusted for additional clinically relevant variables. Intergroup differences in intra-group changes were analyzed using a Poisson test.

RESULTS

Following PSM, the 1,200 mg/day N-AC group (n=104) demonstrated a statistically significant, fully adjusted reduction in exacerbations (-48.6%, P=0.01), hospitalizations (-29.9%, P=0.038), and total exacerbation rates (-54.1%, P=0.002), compared to the 600 mg/day group (n=219). Furthermore, the proportion of patients with more than 20 cc/day of sputum volume and those with mucopurulent sputum decreased by 24.3% (P=0.001) and 8.5% (P=0.041), respectively, in the 1,200 mg/day group versus the 600 mg/day group. No statistically significant difference was observed in the rate of Pseudomonas aeruginosa isolation (-0.9%; P=0.35).

CONCLUSIONS

N-AC at a dose of 1,200 mg/day is more effective than 600 mg/day in reducing exacerbations, hospitalizations, and daily sputum volume in patients with bronchiectasis.

Для цитирования: Oscullo Grace, Méndez Raúl, Olveira Casilda, Girón Rosa, García-Clemente Marta, Máiz Luis, Sibila Oriol, Golpe Rafael, Rodríguez-Hermosa Juan Luis, Barreiro Esther, Prados Concepción, Rodríguez-Lopez Juan, de la Rosa David, Martinez-García Miguel Ángel. What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.. Journal of thoracic disease. 2025. DOI: 10.21037/jtd-2025-1159.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.